Trial Outcomes & Findings for Treatment for Completers of the Study B7A-MC-MBCM (NCT NCT00266695)

NCT ID: NCT00266695

Last Updated: 2016-10-06

Results Overview

The number of participants who experienced SMVL in at least 1 diabetic retinopathy (DR) study eye. SMVL was a ≥15-letter decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) that was sustained for the last 6 months of the study. Best-corrected ETDRS VA was measured at 4 meters (m) using an eye chart with 5 letters per row of decreasing letter size in each successive row. Participants read the chart from the top down until reaching a row where ≥3 letters in the row could not be read correctly. If \<20 letters were read correctly at 4 m, the chart was re-read at 1 m. The best-corrected ETDRS VA score was the total number of letters read correctly per eye at 4 m, plus a correction factor of 30 if ≥20 letters were read correctly at 4 m, plus the total number of letters read correctly at 1 m, if assessed. Best-corrected ETDRS VA scores ranged from 0 (no letters read correctly) to 100 (all letters read correctly).

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

203 participants

Primary outcome timeframe

Baseline, 18 months up to 24 months

Results posted on

2016-10-06

Participant Flow

This study, B7A-MC-MBDV (MBDV), was an open-label extension of Study B7A-MC-MBCM (MBCM; NCT00604383), and was only open to participants who completed Study MBCM. Unless otherwise stated, the time frames refer to this study, MBDV.

Participant milestones

Participant milestones
Measure
Ruboxistaurin
32 milligrams (mg) given once daily as an oral tablet for 2 years.
Overall Study
STARTED
203
Overall Study
COMPLETED
174
Overall Study
NOT COMPLETED
29

Reasons for withdrawal

Reasons for withdrawal
Measure
Ruboxistaurin
32 milligrams (mg) given once daily as an oral tablet for 2 years.
Overall Study
Adverse Event
1
Overall Study
Death
9
Overall Study
Physician Decision
1
Overall Study
Lost to Follow-up
3
Overall Study
Withdrawal by Subject
15

Baseline Characteristics

Treatment for Completers of the Study B7A-MC-MBCM

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Ruboxistaurin
n=203 Participants
32 mg given once daily as oral tablet for 2 years.
Age, Continuous
58.50 years
STANDARD_DEVIATION 9.70 • n=39 Participants
Sex: Female, Male
Female
70 Participants
n=39 Participants
Sex: Female, Male
Male
133 Participants
n=39 Participants
Race/Ethnicity, Customized
Caucasian
180 participants
n=39 Participants
Race/Ethnicity, Customized
Non-Caucasian
23 participants
n=39 Participants
Region of Enrollment
United States
203 participants
n=39 Participants
Diabetes Type
Type 1
24 participants
n=39 Participants
Diabetes Type
Type 2
179 participants
n=39 Participants
Duration of Diabetes
16.08 years
STANDARD_DEVIATION 8.40 • n=39 Participants
Body Mass Index
33.47 kilograms per square meter (kg/m^2)
STANDARD_DEVIATION 7.34 • n=39 Participants
Number of Diabetic Retinopathy (DR) Study Eyes Per Participant
One
72 participant
n=39 Participants
Number of Diabetic Retinopathy (DR) Study Eyes Per Participant
Two
131 participant
n=39 Participants
Visual Acuity (VA) Score
76.84 letters read correctly
STANDARD_DEVIATION 13.11 • n=39 Participants
Blood Pressure
Systolic Blood Pressure
131.48 millimeters of mercury (mm Hg)
STANDARD_DEVIATION 17.03 • n=39 Participants
Blood Pressure
Diastolic Blood Pressure
73.29 millimeters of mercury (mm Hg)
STANDARD_DEVIATION 10.07 • n=39 Participants

PRIMARY outcome

Timeframe: Baseline, 18 months up to 24 months

Population: All enrolled participants.

The number of participants who experienced SMVL in at least 1 diabetic retinopathy (DR) study eye. SMVL was a ≥15-letter decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) that was sustained for the last 6 months of the study. Best-corrected ETDRS VA was measured at 4 meters (m) using an eye chart with 5 letters per row of decreasing letter size in each successive row. Participants read the chart from the top down until reaching a row where ≥3 letters in the row could not be read correctly. If \<20 letters were read correctly at 4 m, the chart was re-read at 1 m. The best-corrected ETDRS VA score was the total number of letters read correctly per eye at 4 m, plus a correction factor of 30 if ≥20 letters were read correctly at 4 m, plus the total number of letters read correctly at 1 m, if assessed. Best-corrected ETDRS VA scores ranged from 0 (no letters read correctly) to 100 (all letters read correctly).

Outcome measures

Outcome measures
Measure
Ruboxistaurin
n=203 Participants
32 mg given once daily as oral tablet for 2 years.
Sustained Moderate Visual Loss (SMVL)
10 participants
Interval 2.0 to 9.0

SECONDARY outcome

Timeframe: End of Study MBCM to the beginning of Study MBDV, approximately 6 to 18 months

Population: All enrolled participants.

The number of participants whose best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) in at least 1 diabetic retinopathy (DR) study eye decreased by 15-letters or less from the conclusion of Study MBCM to the start of Study MBDV, 6 to 18 months later. Best-corrected ETDRS VA was measured at 4 meters (m) using an eye chart with 5 letters per row of decreasing letter size in each successive row. Participants read the chart from the top down until reaching a row where ≥3 letters in the row could not be read correctly. If \<20 letters were read correctly at 4 m, the chart was re-read at 1 m. The best-corrected ETDRS VA score was the total number of letters read correctly per eye at 4 m, plus a correction factor of 30 if ≥20 letters were read correctly at 4 m, plus the total number of letters read correctly at 1 m, if assessed. Best-corrected ETDRS VA scores ranged from 0 (no letters read correctly) to 100 (all letters read correctly).

Outcome measures

Outcome measures
Measure
Ruboxistaurin
n=203 Participants
32 mg given once daily as oral tablet for 2 years.
Vision Loss
22 participants
Interval 7.0 to 16.0

SECONDARY outcome

Timeframe: Baseline in Study MBCM, 18 months up to 24 months in Study MBDV (for a total of 75 up to 87 months of SMVL, long term)

Population: Participants who were treated with 32 milligram (mg) ruboxistaurin once daily in Study MBCM and had at least 1 DR study eye, who were also enrolled in Study MBDV.

The number of participants who experienced SMVL, long term, in at least 1 diabetic retinopathy (DR) study eye. Long term SMVL was a ≥15-letter decrease from Study MBCM baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) that was sustained for the last 6 months of Study MBDV. VA was measured at 4 meters (m) using an eye chart with 5 letters per row of decreasing letter size in each successive row. Participants read the chart from the top down until reaching a row where ≥3 letters in the row could not be read correctly. If \<20 letters were read correctly at 4 m, the chart was re-read at 1 m. The best-corrected ETDRS VA score was the total number of letters read correctly per eye at 4 m, plus a correction factor of 30 if ≥20 letters were read correctly at 4 m, plus the total number of letters read correctly at 1 m, if assessed. Best-corrected ETDRS VA scores ranged from 0 (no letters read correctly) to 100 (all letters read correctly).

Outcome measures

Outcome measures
Measure
Ruboxistaurin
n=103 Participants
32 mg given once daily as oral tablet for 2 years.
Sustained Moderate Vision Loss (SMVL), Long Term
8 participants
Interval 3.0 to 15.0

SECONDARY outcome

Timeframe: Baseline up to 6 months, 6 months up to 12 months, 12 months up to 18 months, 18 months up to 24 months, and 24 months up to 30 months

Population: All enrolled participants (pts) at risk during the specified intervals. Pts who did not experience an event during the interval were censored to the last time point in the interval. Number of pts censored: 0 to 6 months = 2 pts, 6 to 12 months = 4 pts, 12 to 18 months = 9 pts, 18 to 24 months = 82 pts, and 24 to 30 months = 90 pts.

An mSMVL event was defined as a ≥15-letter decrease from Study MBDV baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) during any 6-month period, not just the last 6 months of the study. An mSMVL event was the first occurrence of an mSMVL in a participant, and the time at which the mSMVL began was used as the time of the event for the analysis. VA was measured at 4 meters (m) using an eye chart with 5 letters per row. Participants read the chart from the top down until reaching a row where ≥3 letters in the row could not be read correctly. If \<20 letters were read correctly at 4 m, the chart was re-read at 1 m. The best-corrected ETDRS VA score was the total number of letters read correctly per eye at 4 m, plus a correction factor of 30 if ≥20 letters were read correctly at 4 m, plus the total number of letters read correctly at 1 m, if assessed.

Outcome measures

Outcome measures
Measure
Ruboxistaurin
n=198 Participants
32 mg given once daily as oral tablet for 2 years.
Number of Participants With a Modified Sustained Moderate Vision Loss (mSMVL) Event by Time Interval
6 up to 12 months, n=196
4 participants
Number of Participants With a Modified Sustained Moderate Vision Loss (mSMVL) Event by Time Interval
12 up to 18 months, n=188
5 participants
Number of Participants With a Modified Sustained Moderate Vision Loss (mSMVL) Event by Time Interval
18 up to 24 months, n=174
2 participants
Number of Participants With a Modified Sustained Moderate Vision Loss (mSMVL) Event by Time Interval
24 up to 30 months, n=90
0 participants
Number of Participants With a Modified Sustained Moderate Vision Loss (mSMVL) Event by Time Interval
0 up to 6 months, n=198
0 participants

SECONDARY outcome

Timeframe: Month 24

Population: All enrolled participants. Last observation carried forward (LOCF).

Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) was measured at 4 meters (m) using an eye chart with 5 letters per row of decreasing letter size in each successive row. Participants read the chart from the top down until reaching a row where ≥3 letters in the row could not be read correctly. If \<20 letters were read correctly at 4 m, the chart was re-read at 1 m. The best-corrected ETDRS VA score was the total number of letters read correctly per eye at 4 m, plus a correction factor of 30 if ≥20 letters were read correctly at 4 m, plus the total number of letters read correctly at 1 m, if assessed. Best-corrected ETDRS VA scores ranged from 0 (no letters read correctly) to 100 (all letters read correctly). A higher score represented better VA.

Outcome measures

Outcome measures
Measure
Ruboxistaurin
n=203 Participants
32 mg given once daily as oral tablet for 2 years.
Visual Acuity
75.14 letters read correctly
Standard Deviation 14.92

SECONDARY outcome

Timeframe: Baseline up to Month 24

Population: All enrolled participants.

Outcome measures

Outcome measures
Measure
Ruboxistaurin
n=203 Participants
32 mg given once daily as oral tablet for 2 years.
Number of Participants Receiving Treatment With Focal/Grid Photocoagulation
19 participants
Interval 6.0 to 14.0

SECONDARY outcome

Timeframe: Baseline up to Month 24

Population: All enrolled participants.

Outcome measures

Outcome measures
Measure
Ruboxistaurin
n=203 Participants
32 mg given once daily as oral tablet for 2 years.
Number of Participants Receiving Treatment With Panretinal Photocoagulation
53 participants
Interval 20.0 to 33.0

Adverse Events

Ruboxistaurin

Serious events: 57 serious events
Other events: 166 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Ruboxistaurin
n=203 participants at risk
32 mg given once daily as oral tablet for 2 years.
Blood and lymphatic system disorders
Anaemia
0.49%
1/203 • Number of events 1
Cardiac disorders
Acute myocardial infarction
0.49%
1/203 • Number of events 1
Cardiac disorders
Atrial fibrillation
0.49%
1/203 • Number of events 1
Cardiac disorders
Bradycardia
0.49%
1/203 • Number of events 1
Cardiac disorders
Cardiac arrest
0.49%
1/203 • Number of events 2
Cardiac disorders
Cardiac failure congestive
3.9%
8/203 • Number of events 15
Cardiac disorders
Cardio-respiratory arrest
0.49%
1/203 • Number of events 1
Cardiac disorders
Cardiopulmonary failure
0.49%
1/203 • Number of events 1
Cardiac disorders
Coronary artery disease
3.0%
6/203 • Number of events 6
Cardiac disorders
Hypertensive heart disease
0.49%
1/203 • Number of events 1
Cardiac disorders
Ischaemic cardiomyopathy
0.49%
1/203 • Number of events 1
Cardiac disorders
Myocardial infarction
0.99%
2/203 • Number of events 2
Cardiac disorders
Sick sinus syndrome
0.49%
1/203 • Number of events 1
Cardiac disorders
Ventricular dysfunction
0.49%
1/203 • Number of events 1
Cardiac disorders
Ventricular tachycardia
0.49%
1/203 • Number of events 1
Gastrointestinal disorders
Acute abdomen
0.49%
1/203 • Number of events 1
Gastrointestinal disorders
Erosive oesophagitis
0.49%
1/203 • Number of events 1
Gastrointestinal disorders
Gastric ulcer
0.49%
1/203 • Number of events 1
Gastrointestinal disorders
Gastritis
0.49%
1/203 • Number of events 1
Gastrointestinal disorders
Gastritis erosive
0.49%
1/203 • Number of events 1
Gastrointestinal disorders
Impaired gastric emptying
0.49%
1/203 • Number of events 1
Gastrointestinal disorders
Intestinal obstruction
0.99%
2/203 • Number of events 2
Gastrointestinal disorders
Nausea
0.49%
1/203 • Number of events 1
Gastrointestinal disorders
Oesophagitis
0.49%
1/203 • Number of events 1
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
0.49%
1/203 • Number of events 1
Gastrointestinal disorders
Vomiting
0.49%
1/203 • Number of events 1
General disorders
Chest pain
2.0%
4/203 • Number of events 4
General disorders
Death
0.49%
1/203 • Number of events 1
General disorders
Generalised oedema
0.49%
1/203 • Number of events 1
General disorders
Oedema peripheral
0.49%
1/203 • Number of events 1
Infections and infestations
Appendicitis
0.49%
1/203 • Number of events 1
Infections and infestations
Arthritis infective
0.49%
1/203 • Number of events 1
Infections and infestations
Bronchitis
0.49%
1/203 • Number of events 1
Infections and infestations
Cellulitis
3.4%
7/203 • Number of events 8
Infections and infestations
Endocarditis
0.49%
1/203 • Number of events 1
Infections and infestations
Gangrene
0.49%
1/203 • Number of events 1
Infections and infestations
Gastroenteritis
0.49%
1/203 • Number of events 1
Infections and infestations
Gastroenteritis viral
0.49%
1/203 • Number of events 1
Infections and infestations
Infection
0.49%
1/203 • Number of events 1
Infections and infestations
Kidney infection
0.49%
1/203 • Number of events 1
Infections and infestations
Localised infection
0.49%
1/203 • Number of events 1
Infections and infestations
Osteomyelitis
2.0%
4/203 • Number of events 4
Infections and infestations
Pneumonia
2.0%
4/203 • Number of events 4
Infections and infestations
Pyelonephritis acute
0.49%
1/203 • Number of events 1
Infections and infestations
Septic shock
0.49%
1/203 • Number of events 1
Infections and infestations
Sinusitis
0.49%
1/203 • Number of events 1
Infections and infestations
Staphylococcal abscess
0.49%
1/203 • Number of events 1
Infections and infestations
Staphylococcal bacteraemia
0.49%
1/203 • Number of events 1
Infections and infestations
Urinary tract infection
1.5%
3/203 • Number of events 3
Infections and infestations
Urosepsis
0.49%
1/203 • Number of events 1
Infections and infestations
Viral infection
0.49%
1/203 • Number of events 1
Infections and infestations
Wound infection staphylococcal
0.49%
1/203 • Number of events 1
Injury, poisoning and procedural complications
Acetabulum fracture
0.49%
1/203 • Number of events 1
Injury, poisoning and procedural complications
Foot fracture
0.49%
1/203 • Number of events 1
Injury, poisoning and procedural complications
Hip fracture
0.49%
1/203 • Number of events 1
Injury, poisoning and procedural complications
Lower limb fracture
0.49%
1/203 • Number of events 1
Injury, poisoning and procedural complications
Pocket erosion
0.49%
1/203 • Number of events 1
Injury, poisoning and procedural complications
Rib fracture
0.49%
1/203 • Number of events 1
Injury, poisoning and procedural complications
Subdural haematoma
0.49%
1/203 • Number of events 1
Investigations
Heart rate irregular
0.99%
2/203 • Number of events 2
Metabolism and nutrition disorders
Dehydration
1.5%
3/203 • Number of events 3
Metabolism and nutrition disorders
Diabetes mellitus inadequate control
0.49%
1/203 • Number of events 1
Metabolism and nutrition disorders
Hyperglycaemia
0.49%
1/203 • Number of events 1
Metabolism and nutrition disorders
Hypoglycaemia
0.49%
1/203 • Number of events 1
Metabolism and nutrition disorders
Hypokalaemia
0.49%
1/203 • Number of events 1
Metabolism and nutrition disorders
Type 2 diabetes mellitus
0.49%
1/203 • Number of events 1
Musculoskeletal and connective tissue disorders
Fistula
0.49%
1/203 • Number of events 1
Musculoskeletal and connective tissue disorders
Pain in extremity
0.49%
1/203 • Number of events 1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoma
0.49%
1/203 • Number of events 1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer
0.49%
1/203 • Number of events 1
Nervous system disorders
Brain stem infarction
0.49%
1/203 • Number of events 1
Nervous system disorders
Carotid artery occlusion
0.49%
1/203 • Number of events 1
Nervous system disorders
Cerebrovascular accident
0.49%
1/203 • Number of events 1
Nervous system disorders
Cervicobrachial syndrome
0.49%
1/203 • Number of events 1
Nervous system disorders
Coma
0.49%
1/203 • Number of events 1
Nervous system disorders
Dizziness
0.49%
1/203 • Number of events 1
Nervous system disorders
Syncope
1.5%
3/203 • Number of events 3
Nervous system disorders
Transient ischaemic attack
0.99%
2/203 • Number of events 2
Renal and urinary disorders
Diabetic nephropathy
0.49%
1/203 • Number of events 1
Renal and urinary disorders
Renal failure acute
3.0%
6/203 • Number of events 6
Respiratory, thoracic and mediastinal disorders
Asthma
0.49%
1/203 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
0.49%
1/203 • Number of events 2
Respiratory, thoracic and mediastinal disorders
Dyspnoea
1.5%
3/203 • Number of events 3
Respiratory, thoracic and mediastinal disorders
Epistaxis
0.49%
1/203 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
0.49%
1/203 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Pleural effusion
0.49%
1/203 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
0.49%
1/203 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
0.49%
1/203 • Number of events 1
Respiratory, thoracic and mediastinal disorders
Respiratory failure
1.5%
3/203 • Number of events 4
Skin and subcutaneous tissue disorders
Hyperhidrosis
0.49%
1/203 • Number of events 1
Surgical and medical procedures
Toe amputation
0.49%
1/203 • Number of events 1
Vascular disorders
Arteriosclerosis
0.49%
1/203 • Number of events 1
Vascular disorders
Hypertensive emergency
0.49%
1/203 • Number of events 1
Vascular disorders
Hypotension
0.99%
2/203 • Number of events 2
Vascular disorders
Malignant hypertension
0.49%
1/203 • Number of events 1
Vascular disorders
Orthostatic hypotension
0.49%
1/203 • Number of events 1
Vascular disorders
Peripheral vascular disorder
0.49%
1/203 • Number of events 1

Other adverse events

Other adverse events
Measure
Ruboxistaurin
n=203 participants at risk
32 mg given once daily as oral tablet for 2 years.
Eye disorders
Vitreous haemorrhage
9.9%
20/203 • Number of events 25
Gastrointestinal disorders
Diarrhoea
7.9%
16/203 • Number of events 19
Infections and infestations
Bronchitis
5.9%
12/203 • Number of events 14
Infections and infestations
Nasopharyngitis
10.8%
22/203 • Number of events 32
Infections and infestations
Upper respiratory tract infection
5.4%
11/203 • Number of events 11
Infections and infestations
Urinary tract infection
6.4%
13/203 • Number of events 21
Musculoskeletal and connective tissue disorders
Back pain
8.9%
18/203 • Number of events 20
Respiratory, thoracic and mediastinal disorders
Cough
7.4%
15/203 • Number of events 19
Surgical and medical procedures
Cataract operation
7.4%
15/203 • Number of events 20
Surgical and medical procedures
Retinal laser coagulation
24.1%
49/203 • Number of events 111
Surgical and medical procedures
Vitrectomy
5.9%
12/203 • Number of events 16

Additional Information

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: GT60